+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Autoimmune Drugs Market 2018-2022 - Product Image

Global Autoimmune Drugs Market 2018-2022

  • ID: 4721491
  • Report
  • Region: Global
  • 124 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB
  • MORE
High cost of autoimmune drugs to drive market growth. Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs. The analysts have predicted that the autoimmune drugs market will register a CAGR of more than 8% by 2022.

Market Overview

Targeted therapeutic mechanism of biologics

By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.

Reimbursement challenges of autoimmune drugs

The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.

For the detailed list of factors that will drive and challenge the growth of the autoimmune drugs market during the 2018-2022, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company, the competitive environment is quite intense. Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs, will provide considerable growth opportunities to autoimmune drugs manufactures. AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB are some of the major companies covered in this report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
  • Segmentation by therapy area
  • Comparison by therapy area
  • Rheumatoid arthritis - Market size and forecast 2017-2022
  • Multiple sclerosis - Market size and forecast 2017-2022
  • Psoriasis - Market size and forecast 2017-2022
  • Inflammatory bowel disease - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by therapy area
PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULE
  • Segmentation by type of molecule
  • Biologics
  • Small molecules
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: mAbs and biologics for autoimmune diseases
Exhibit 06: Small molecules for autoimmune diseases
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global - Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Biosimilars approved in 2017
Exhibit 12: Global - Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition - Five forces 2017
Exhibit 21: Therapy area - Market share 2017-2022 (%)
Exhibit 22: Comparison by therapy area
Exhibit 23: Rheumatoid arthritis - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Rheumatoid arthritis - Year-over-year growth 2018-2022 (%)
Exhibit 25: Multiple sclerosis - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Multiple sclerosis - Year-over-year growth 2018-2022 (%)
Exhibit 27: Psoriasis - Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Psoriasis - Year over year growth 2018-2022 (%)
Exhibit 29: Inflammatory bowel disease - Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Inflammatory bowel disease - Year-over-year growth 2018-2022 (%)
Exhibit 31: Others - Market size and forecast 2017-2022 ($ bn)
Exhibit 32: Others - Year-over-year growth 2018-2022 (%)
Exhibit 33: Market opportunity by therapy area
Exhibit 34: Customer landscape
Exhibit 35: Global - Market share by geography 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Molecules in the pipeline for autoimmune disorders in the Americas
Exhibit 39: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in Americas
Exhibit 41: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 42: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in EMEA
Exhibit 44: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 45: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 46: Top 3 countries in APAC
Exhibit 47: Market opportunity
Exhibit 48: Sales of major autoimmune drugs
Exhibit 49: Patent expiration dates for some of the biologics
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie overview
Exhibit 56: AbbVie - Business segments
Exhibit 57: AbbVie - Organizational developments
Exhibit 58: AbbVie - Geographic focus
Exhibit 59: AbbVie - Key offerings
Exhibit 60: Amgen overview
Exhibit 61: Amgen - Business segments
Exhibit 62: Amgen - Organizational developments
Exhibit 63: Amgen - Geographic focus
Exhibit 64: Amgen - Key offerings
Exhibit 65: Johnson & Johnson overview
Exhibit 66: Johnson & Johnson - Business segments
Exhibit 67: Johnson & Johnson - Organizational developments
Exhibit 68: Johnson & Johnson - Geographic focus
Exhibit 69: Johnson & Johnson - Segment focus
Exhibit 70: Johnson & Johnson - Key offerings
Exhibit 71: Novartis overview
Exhibit 72: Novartis - Business segments
Exhibit 73: Novartis - Organizational developments
Exhibit 74: Novartis - Geographic focus
Exhibit 75: Novartis - Segment focus
Exhibit 76: Novartis - Key offerings
Exhibit 77: Pfizer overview
Exhibit 78: Pfizer - Business segments
Exhibit 79: Pfizer - Organizational developments
Exhibit 80: Pfizer - Geographic focus
Exhibit 81: Pfizer - Segment focus
Exhibit 82: Pfizer - Key offerings
Exhibit 83: UCB overview
Exhibit 84: UCB - Business segments
Exhibit 85: UCB - Organizational developments
Exhibit 86: UCB - Geographic focus
Exhibit 87: UCB - Segment focus
Exhibit 88: UCB - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB
  • MORE
Global Autoimmune Drugs Market 2018-2022

The analyst recognizes the following companies as the key players in the global autoimmune drugs market: AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the high cost of autoimmune drugs.”

According to the report, one of the major drivers for this market is the targeted therapeutic mechanism of biologics.

Further, the report states that one of the major factors hindering the growth of this market is the reimbursement challenges of autoimmune drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4721491
Adroll
adroll